TLC-2716

Phase 2Small molecule

OOrsoBio, Inc

TLC-2716 is one of 45 small molecule programs targeting Hypertriglyceridemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertriglyceridemiaActive, not recruiting

HypertriglyceridemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

63 competitors in Hypertriglyceridemia

#DrugCompanyPhaseTrials

Cipro

Selzentry

Lopid

Lovaza

3 5

Zocor

OOrganon and Co

Approved

—6

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 7

Zetia

Statin

1 9

EVKEEZA

Regeneron

Phase 2

2 10

Ciprofibrate

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertriglyceridemia1 trial

Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

Recruiting·OOrsoBio, Inc·Phase 2·NCT06564584·30 enrolled

ART1 trial

A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants

Completed·OOrsoBio, Inc·Phase 1·NCT05483998·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TLC-2716. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TLC-2716 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TLC-2716. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OrsoBio, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOrsoBio, Inc

TLC-2716

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypertriglyceridemia1 trial

ART1 trial

References

Drug Info

Quick Facts

Related News